7 completed, 2 terminated, 1 suspended. 7 Phase 2, 5 Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 2, Suspended 1 |
| Phase 1 | 5 | Completed 3, Suspended 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow CoMentis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia APN1125, Placebo - Schizophrenia | Phase 1 / Phase 2 | Suspended | CoMentis | 30 | 2016-04-01 | 2016-07-13 |
| Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects APN1125, Placebo - Schizophrenia | Phase 1 | Completed | CoMentis | 58 | 2014-12-01 | 2016-04-08 |
| Anti-inflammatory Effects of GTS-21 After LPS GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride], Placebo, Lipopolysaccharide E. Coli 113:H 10:K negative - Endotoxemia, Sepsis | Not applicable | Completed | Radboud University Medical Center | 12 | 2008-08-01 | 2010-11-05 |
| Safety and Efficacy of ATG003 in Patients With AMD Receiving Anti-VEGF ATG003 (mecamylamine), Placebo - Age-Related Macular Degeneration | Phase 2 | Completed | CoMentis | 60 | 2008-05-01 | 2010-10-28 |
| Topical Ocular Mecamylamine in Diabetic Macular Edema (DME) mecamylamine - Diabetic Macular Edema | Phase 2 | Completed | CoMentis | 2007-09-01 | 2008-04-08 | |
| Safety Study of CTS21166 to Treat Alzheimer Disease CTS21166 (ZPQ-21166) - Alzheimer's Disease | Phase 1 | Completed | CoMentis | 56 | 2007-06-01 | 2008-07-09 |
| Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD) Mecamylamine, Placebo - Macular Degeneration | Phase 2 | Terminated | CoMentis | 343 | 2007-03-01 | 2010-11-23 |
| Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder GTS21/Placebo - Attention Deficit Hyperactivity Disorder | Phase 1 / Phase 2 | Completed | CoMentis | 37 | 2007-02-01 | 2010-09-10 |
| GTS21-201 for Alzheimer Disease:GTS-21 Administered Daily for 28 Days to Participants With Probable Alzheimer's Disease DMXB-A - Alzheimer Disease | Phase 2 | Completed | CoMentis | 60 | 2006-11-01 | 2007-04-19 |
| Safety and Preliminary Efficacy Study of Nicotine Gel to Treat Diabetic Foot Ulcers ATG002 (study drug) - Diabetic Foot Ulcers | Phase 1 / Phase 2 | Terminated | CoMentis | 48 | 2006-10-01 | 2007-08-09 |
Alzheimer Disease (2) · Macular Degeneration (2) · Schizophrenia (2) · Attention Deficit Disorder with Hyperactivity (1) · Diabetes Mellitus (1) · Diabetic Foot (1) · Endotoxemia (1) · Foot Ulcer (1) · Macular Edema (1) · Sepsis (1)
3-(2,4-dimethoxybenzylidene)anabaseine (3) · Mecamylamine (3) · Drug Evaluation (1) · Endotoxins (1)
United States (7) · Brazil (1) · Czechia (1) · Mexico (1) · Netherlands (1) · Poland (1) · Russia (1) · Ukraine (1)
Carl Grove (2) · Henry Hsu, MD (2) · Carl Grove, MS (1) · David Han, MD (1) · David P Walling, PhD (1) · Henry Hsu, M.D. (1)